About Fosun Kite

As a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and U.S. Kite Pharma, Fosun Kite Biotechnology Co., Ltd. (hereinafter referred as "Fosun Kite") was established in April 2017 in Shanghai China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.

Technology Acquisition and independent R&D

Yescarta is the world's first approved CAR-T cell therapy for adult patients with certain types of non-Hodgkin lymphoma (NHL). FDA approved Kite Pharma’s Yescarca for the US market in October, 2017, followed by EMA for EU markets in August, 2018. According to the ZUMA-1 clinical results released by Kite Pharma, among 101 patients with refractory large B-cell lymphoma, at two years after being treated with Yescarta, the best objective response showed an overall response rate of 83%, with 58% of patients having achieved a complete response1. At a median of 15.4 months post-infusion, 42% of patients remained in response, including 40% in complete remission2. At a median of 27.1 months post-infusion, 39% of patients remained in response, including 37% in complete remission1.

Fosun Kite had brought in the technology of Yescarta from Kite Pharma and developed it in China. New Drug Application (NDA) filing of Fosun Kite was accepted by China National Medical Products Administration (NMPA) in February 2020, and followed by a priority review status granted in March.

Meantime, by building independent R&D capability, Fosun Kite is committed to developing more innovative immunotherapy products to enrich the company's pipeline and open up for more therapeutic areas.

Reference
1. Locke et al. Lancet Oncol. 2019 Jan;20(1):31-42;
2. Neelapu SS, et al. N Engl J Med 2017; 377(26):2531-2544